TY - JOUR
T1 - Zolpidem arousing effect in persistent vegetative state patients
T2 - Autonomic, EEG and behavioral assessment
AU - Machado, Calixto
AU - Estévez, Mario
AU - Rodríguez, Rafael
AU - Pérez-Nellar, Jesús
AU - Chinchilla, Mauricio
AU - DeFina, Philip
AU - Leisman, Gerry
AU - Carrick, Frederick R.
AU - Melillo, Robert
AU - Schiavi, Adam
AU - Gutiérrez, Joel
AU - Carballo, Maylén
AU - Machado, Andrés
AU - Olivares, Ana
AU - Pérez-Cruz, Nuvia
PY - 2014
Y1 - 2014
N2 - Objective. To study the Zolpidem arousing effect in persistent vegetative state (PVS) patients combining clinical evaluation, autonomic assessment by heart rate variability (HRV), and EEG records. Methods. We studied a group of 8 PVS patients and other 8 healthy control subjects, matched by age and gender. The patients and controls received drug or placebo in two experimental sessions, separated by 10-14 days. The first 30 minutes of the session were considered the basal record, and then Zolpidem was administered. All participants were evaluated clinically, by EEG, and by HRV during the basal record, and for 90 minutes after drug intake. Results. We found in all patients, time-related arousing signs after Zolpidem intake: behavioral (yawns and hiccups), activation of EEG cortical activity, and a vagolytic chronotropic effect without a significant increment of the vasomotor sympathetic tone. Conclusions. We demonstrated time-related arousing signs after Zolpidem intake. We discussed possible mechanisms to explain these patho-physiological findings regarding EEG cortical activation and an autonomic vagolytic drug effect. As this autonomic imbalance might induce cardiocirculatory complications, which we didn't find in any of our patients, we suggest developing future trials under control of physiological indices by bedside monitoring. However, considering that this arousing Zolpidem effect might be certainly related to brain function improvement, it should be particularly considered for the development of new neuro-rehabilitation programs in PVS cases. According to the literature review, we claim that this is the first report about the vagolitic effect of Zolpidem in PVS cases.
AB - Objective. To study the Zolpidem arousing effect in persistent vegetative state (PVS) patients combining clinical evaluation, autonomic assessment by heart rate variability (HRV), and EEG records. Methods. We studied a group of 8 PVS patients and other 8 healthy control subjects, matched by age and gender. The patients and controls received drug or placebo in two experimental sessions, separated by 10-14 days. The first 30 minutes of the session were considered the basal record, and then Zolpidem was administered. All participants were evaluated clinically, by EEG, and by HRV during the basal record, and for 90 minutes after drug intake. Results. We found in all patients, time-related arousing signs after Zolpidem intake: behavioral (yawns and hiccups), activation of EEG cortical activity, and a vagolytic chronotropic effect without a significant increment of the vasomotor sympathetic tone. Conclusions. We demonstrated time-related arousing signs after Zolpidem intake. We discussed possible mechanisms to explain these patho-physiological findings regarding EEG cortical activation and an autonomic vagolytic drug effect. As this autonomic imbalance might induce cardiocirculatory complications, which we didn't find in any of our patients, we suggest developing future trials under control of physiological indices by bedside monitoring. However, considering that this arousing Zolpidem effect might be certainly related to brain function improvement, it should be particularly considered for the development of new neuro-rehabilitation programs in PVS cases. According to the literature review, we claim that this is the first report about the vagolitic effect of Zolpidem in PVS cases.
KW - Arousal
KW - Autonomic
KW - EEG
KW - Heart rate variability
KW - Persistent vegetative state
KW - Zolpidem
UR - http://www.scopus.com/inward/record.url?scp=84904728023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904728023&partnerID=8YFLogxK
M3 - Review article
C2 - 24025063
AN - SCOPUS:84904728023
SN - 1381-6128
VL - 20
SP - 4185
EP - 4202
JO - Current pharmaceutical design
JF - Current pharmaceutical design
IS - 26
ER -